<!doctype html>
<html>

<head>

  <title>
    
      MS progression despite high-efficacy therapy. | Synaptic Transmissions
    
  </title>

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta charset="utf-8">

  <link rel="stylesheet" href="/assets/css/main.css">
  <link rel="stylesheet" href="/assets/css/syntax.css">
  <link type="application/atom+xml" rel="alternate" href="/feed.xml" title="Synaptic Transmissions" />

  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=PT+Serif:400,400italic,700%7CPT+Sans:400">
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Source+Code+Pro">
  <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Quattrocento+Sans">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
  <link rel="stylesheet" type="text/css" href="https://cdn.jsdelivr.net/npm/cookieconsent@3/build/cookieconsent.min.css" />

  <script type="text/javascript" async
    src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js?config=TeX-MML-AM_CHTML">
    MathJax.Hub.Config({
        tex2jax: {
          inlineMath: [['$', '$'], ['\\(', '\\)']]
        }
      });
  </script>

  <!-- Google Analytics -->
  <script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', '', 'auto');
  ga('send', 'pageview');
</script>


  <!-- Use Jekyll SEO plugin -->
  <!-- Begin Jekyll SEO tag v2.8.0 -->
<title>MS progression despite high-efficacy therapy. | Synaptic Transmissions</title>
<meta name="generator" content="Jekyll v4.4.1" />
<meta property="og:title" content="MS progression despite high-efficacy therapy." />
<meta name="author" content="Habakuk Hain" />
<meta property="og:locale" content="en_US" />
<meta name="description" content="Problem: There is a paradigmatic shift in MS care on its way as evidence is accumulating that using high-efficacy therapies (HET) in early stages of the disease prevents relapses and decreases evidence of disease activity on sequential MRI scans. Whether high-efficacy MS therapies can prevent progression independent of relapse and MRI activity (PIRMA) is an open questions." />
<meta property="og:description" content="Problem: There is a paradigmatic shift in MS care on its way as evidence is accumulating that using high-efficacy therapies (HET) in early stages of the disease prevents relapses and decreases evidence of disease activity on sequential MRI scans. Whether high-efficacy MS therapies can prevent progression independent of relapse and MRI activity (PIRMA) is an open questions." />
<meta property="og:site_name" content="Synaptic Transmissions" />
<meta property="og:type" content="article" />
<meta property="article:published_time" content="2026-02-21T15:04:48+00:00" />
<meta name="twitter:card" content="summary" />
<meta property="twitter:title" content="MS progression despite high-efficacy therapy." />
<script type="application/ld+json">
{"@context":"https://schema.org","@type":"BlogPosting","author":{"@type":"Person","name":"Habakuk Hain"},"dateModified":"2026-02-21T15:04:48+00:00","datePublished":"2026-02-21T15:04:48+00:00","description":"Problem: There is a paradigmatic shift in MS care on its way as evidence is accumulating that using high-efficacy therapies (HET) in early stages of the disease prevents relapses and decreases evidence of disease activity on sequential MRI scans. Whether high-efficacy MS therapies can prevent progression independent of relapse and MRI activity (PIRMA) is an open questions.","headline":"MS progression despite high-efficacy therapy.","mainEntityOfPage":{"@type":"WebPage","@id":"/posts/transmission-3/"},"url":"/posts/transmission-3/"}</script>
<!-- End Jekyll SEO tag -->


</head>


<body>

  <div class="container">
    <header class="masthead">
  <h3 class="masthead-title">
    <a href="/">Synaptic Transmissions</a>
    <small class="masthead-subtitle">Central Latency Reduction</small>
    <div class="menu">
  <nav class="menu-content">
    
      
      <a href="/posts/">Posts</a>
    
      
      <a href="/questions/">Questions</a>
    
      
      <a href="/about/">About</a>
    
  </nav>
  <nav class="social-icons">
    
  
  
    <a href="https://www.github.com/habakukhain" target="_blank"><i class="fa fa-github" aria-hidden="true"></i></a>
  

  
  
    <a href="mailto:habakuk@e-hain.de" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a>
  

  
  
    <a href="/feed.xml"><i class="fa fa-rss-square" aria-hidden="true"></i></a>
  

  </nav>
</div>

  </h3>
</header>


    <div class="post-container">
      



  
  
  
    
    
  
    
    
  
    
    
      
  



<p class="post-type-description">
  <em>Brief transmissions from the neural frontier.</em>
</p>


<h1>
  Transmission #3: MS progression despite high-efficacy therapy.
</h1>



<blockquote class="paper-summary">
  Large French registry study of 10,499 MS patients found that high-efficacy therapies (HET) do not meaningfully prevent progression independent of relapse and MRI activity (PIRMA) compared to moderate-efficacy therapies, despite better control of inflammatory activity. This challenges the assumption that more potent anti-inflammatory treatments will prevent all forms of disability progression in MS.
</blockquote>

<p class="paper-citation">
  Rollot <em>et al</em>, <em>Brain</em> 2026: Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis.  <a href="https://doi.org/10.1093/brain/awag060">Read the full paper.</a>
</p>




<p><strong>Problem</strong>: There is a paradigmatic shift in MS care on its way as evidence is accumulating that using high-efficacy therapies (HET) in early stages of the disease prevents relapses and decreases evidence of disease activity on sequential MRI scans. Whether high-efficacy MS therapies can prevent progression independent of relapse and MRI activity (PIRMA) is an open questions.</p>

<p><strong>Result</strong>: HET showed no meaningful advantage over moderate-efficacy therapies in preventing PIRMA, despite superior control of relapse-associated and MRI-associated worsening.</p>

<p><strong>Open Questions</strong>: The underlying mechanisms driving PIRMA remain unclear, and whether alternative therapeutic strategies beyond current anti-inflammatory approaches might be needed to address this form of progression.</p>




<span class="post-date">
  Written on
  
  February
  21st
    ,
  2026
  by
  
    Habakuk Hain
  
</span>

<!-- <div class="post-date">Feel free to share!</div>
  <div class="sharing-icons">
    <a href="https://twitter.com/intent/tweet?text=MS progression despite high-efficacy therapy.&amp;url=/posts/transmission-3/" target="_blank"><i class="fa fa-twitter" aria-hidden="true"></i></a>
    <a href="https://www.facebook.com/sharer/sharer.php?u=/posts/transmission-3/&amp;title=MS progression despite high-efficacy therapy." target="_blank"><i class="fa fa-facebook" aria-hidden="true"></i></a>
  </div>
</div>
 -->

<!-- <div class="related">
  <h1 >You may also enjoy:</h1>
  
  <ul class="related-posts">
    
      
        
        
      
    
      
        
        
      
    
      
        
        
      
    
  </ul>
</div>
 -->

<section class="comments">
  <script src="https://giscus.app/client.js"
          data-repo="habakukhain/synaptictransmissions"
          data-repo-id="R_kgDORQ_-Ow"
          data-category="General"
          data-category-id="DIC_kwDORQ_-O84C2gcC"
          data-mapping="pathname"
          data-strict="0"
          data-reactions-enabled="1"
          data-emit-metadata="0"
          data-input-position="top"
          data-theme="light"
          data-lang="en"
          data-loading="lazy"
          crossorigin="anonymous"
          async>
  </script>
</section>


    </div>

    <footer class="footer">
  
  
  
    <a href="https://www.github.com/habakukhain" target="_blank"><i class="fa fa-github" aria-hidden="true"></i></a>
  

  
  
    <a href="mailto:habakuk@e-hain.de" target="_blank"><i class="fa fa-envelope" aria-hidden="true"></i></a>
  

  
  
    <a href="/feed.xml"><i class="fa fa-rss-square" aria-hidden="true"></i></a>
  

  <div class="post-date"><a href="">back home to Synaptic Transmissions</a></div>
</footer>


  </div>

<script src="https://cdn.jsdelivr.net/npm/cookieconsent@3/build/cookieconsent.min.js" data-cfasync="false"></script>
<script>
window.cookieconsent.initialise({
  "palette": {
    "popup": {
      "background": "#eaf7f7",
      "text": "#5c7291"
    },
    "button": {
      "background": "#56cbdb",
      "text": "#ffffff"
    }
  },
  "theme": "edgeless",
  "content": {
    "message": "This website is using cookies to allow for more functionality (comments, etc.)",
    "dismiss": "Okay"
  }
});
</script>

</body>
</html>
